EpCAM-targeted liposomal si-RNA delivery for treatment of epithelial cancer

References

• Aggarwal P, Hall JB, McLeland CB, et al. (2009). Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv Drug Deliv Rev 61:428–37
   PubMed Web of Science ®Google Scholar
• Allard WJ, Matera J, Miller MC, et al. (2005). Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. 10(20):6897–904
   Google Scholar
• Allen TM, Cullis PR. (2004). Drug delivery systems: entering the mainstream. Science 303:1818–22
   PubMed Web of Science ®Google Scholar
• Barton GM, Medzhitov R. (2002). Retroviral delivery of small interfering RNA into primary cells. Proc Natl Acad Sci 99:14943–5
   PubMed Web of Science ®Google Scholar
• Casals E, Galán AM, Escolar G, et al. (2003). Physical stability of liposomes bearing hemostatic activity. Chem Phys Lipids 125:139–46
   PubMed Web of Science ®Google Scholar
• Chono S, Li S-D, Conwell CC, Huang L. (2008). An efficient and low immunostimulatory nanoparticle formulation for systemic siRNA delivery to the tumor. J Control Release 131:64–9
   PubMed Web of Science ®Google Scholar
• Conti DS, Brewer D, Grashik J, et al. (2014). Poly(amidoamine) dendrimer nanocarriers and their aerosol formulations for siRNA delivery to the lung epithelium. Mol Pharm 11:1808–22
   PubMed Web of Science ®Google Scholar
• Daniel A. Balazs, Godbey WT. (2001). Liposomes for use in gene delivery. J Drug Deliv 12:2011:326497. doi.org/10.1155/2011/326497
   Google Scholar
• Farhood H, Serbina N, Uuang L. (1995). The role of dioleoyl phosphatidylethanolamine in cationic liposome mediated gene transfer. Biochim Biophys Acta - Biomembr 1235:289–95
   PubMed Web of Science ®Google Scholar
• Gao K, Huang L. (2008). Reviews: nonviral methods for siRNA delivery. Mol Pharm 6:651–8
   Web of Science ®Google Scholar
• Hacein-Bey-Abina S, von Kalle C, Schmidt M, et al. (2003). Serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 349:255–6
   Web of Science ®Google Scholar
• Huang L, Farhood H, Serbina N, et al. (1995). Endosomolytic activity of cationic liposomes enhances the delivery of human immunodeficiency virus-1 trans-activator protein (TAT) to mammalian cells. Biochem Biophys Res Commun 217:761–8
   PubMed Web of Science ®Google Scholar
• Hussain S, Plückthun A, Allen TM, Zangemeister-Wittke U. (2006). Chemosensitization of carcinoma cells using epithelial cell adhesion molecule-targeted liposomal antisense against bcl-2/bcl-xL. Molecular Cancer Ther 5:3170–80
   PubMed Web of Science ®Google Scholar
• Immordino ML, Dosio F, Cattel L. (2006). Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine 1:297–315
   PubMed Web of Science ®Google Scholar
• Inoue Y, Kurihara R, Tsuchida A, et al. (2008). Efficient delivery of siRNA using dendritic poly(L-Lysine) for loss-of-function analysis. J Control Release 126:59–66
   PubMed Web of Science ®Google Scholar
• Ishida T, Harashima H, Kiwada H. (2002). Liposome clearance. Biosci Rep 22:197–224
   PubMed Web of Science ®Google Scholar
• Juliano R, Bauman J, Kang H, Ming X. (2009). Biological barriers to therapy with antisense and siRNA oligonucleotides. Mol Pharm 6:686–95
   PubMed Web of Science ®Google Scholar
• Kapoor M, Burgess DJ. (2012). Physicochemical characterization of anionic lipid-based ternary siRNA complexes. Biochim Biophys Acta 1818:1603–12
   PubMed Web of Science ®Google Scholar
• Keck CM, Jansch M, Müller RH. (2012). Protein adsorption patterns and analysis on IV nanoemulsions – the key factor determining the organ distribution. Pharmaceutics 5:36–68
   PubMedGoogle Scholar
• Kodama Y, Nakamura T, Kurosaki T, et al. (2014). Biodegradable nanoparticles composed of dendrigraft poly-l-lysine for gene delivery. Eur J Pharm Biopharm 87:472–9
   PubMed Web of Science ®Google Scholar
• Kong F, Zhou F, Ge L, et al. (2012). Mannosylated liposomes for targeted gene delivery. Int J Nanomedicine 7:1079–89
   PubMed Web of Science ®Google Scholar
• Li Y, Cheng Q, Jiang Q, et al. (2014). Enhanced endosomal/lysosomal escape by distearoyl phosphoethanolamine-polycarboxybetaine lipid for systemic delivery of siRNA. J Control Release 176:104–14
   PubMed Web of Science ®Google Scholar
• Lonez C, Vandenbranden M, Ruysschaert J-M. (2008). Cationic liposomal lipids: from gene carriers to cell signaling. Prog Lipid Res 47:340–7
   PubMed Web of Science ®Google Scholar
• Ma Z, Yang C, Song W, et al. (2014). Chitosan hydrogel as siRNA vector for prolonged gene silencing. J Nanobiotechnology 12:23
   PubMed Web of Science ®Google Scholar
• Mitra M, Kandalam M, Verma RS, et al. (2010). Genome-wide changes accompanying the knockdown of Ep-CAM in retinoblastoma. Mol Vis 16:828–42
   PubMed Web of Science ®Google Scholar
• Moghaddam B, McNeil SE, Zheng Q, et al. (2011). Exploring the correlation between lipid packaging in lipoplexes and their transfection efficacy. Pharmaceutics 3:848–64
   PubMedGoogle Scholar
• Nabzdyk CS, Chun MC, Oliver-Allen HS, et al. (2014). Gene silencing in human aortic smooth muscle cells induced by PEI-siRNA complexes released from dip-coated electrospun poly(ethylene terephthalate) grafts. Biomaterials 35:3071–9
   PubMed Web of Science ®Google Scholar
• Nag OK, Awasthi V. (2013). Surface engineering of liposomes for stealth behavior. Pharmaceutics 5:542–69
   PubMedGoogle Scholar
• Oh Y-K, Park TG. (2009). siRNA Delivery systems for cancer treatment. Adv Drug Deliv Rev 61:850–62
   PubMed Web of Science ®Google Scholar
• Osta WA, Chen Y, Mikhitarian K, et al. (2004). EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res 64:5818–24
   PubMed Web of Science ®Google Scholar
• Ozpolat B, Sood AK, Lopez-Berestein G. (2014). Liposomal siRNA nanocarriers for cancer therapy. Adv Drug Deliv Rev 66:110–16
   PubMed Web of Science ®Google Scholar
• Pai SI, Lin Y-Y, Macaes B, et al. (2005). Prospects of RNA interference therapy for cancer. Gene Ther 13:464–77
   Web of Science ®Google Scholar
• Pan X, Wu G, Yang W, et al. (2007). Synthesis of cetuximab-immunoliposomes via a cholesterol-based membrane anchor for targeting of EGFR. Bioconjug Chem 18:101–8
   PubMed Web of Science ®Google Scholar
• Patil ML, Zhang M, Betigeri S, et al. (2008). Surface-modified and internally cationic polyamidoamine dendrimers for efficient siRNA delivery. Bioconjug Chem 19:1396–403
   PubMed Web of Science ®Google Scholar
• Ramana LN, Sethuraman S, Ranga U, Krishnan UM. (2010). Development of a liposomal nanodelivery system for nevirapine. J Biomed Sci 17:57
   PubMed Web of Science ®Google Scholar
• Ramana LN, Sharma S, Sethuraman S, et al. (2012). Investigation on the stability of saquinavir loaded liposomes: implication on stealth, release characteristics and cytotoxicity. Int J Pharm 431:120–9
   PubMed Web of Science ®Google Scholar
• Raper SE, Chirmule N, Lee FS, et al. (2003). Fatal systemic inflammatory response syndrome in an ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metlab 80:148–58
   PubMed Web of Science ®Google Scholar
• Sabín J, Prieto G, Ruso JM, et al. (2006). Size and stability of liposomes: a possible role of hydration and osmotic forces. Eur Phys J E Soft Matter 20:401–8
   PubMed Web of Science ®Google Scholar
• Sankpal NV, Mayfield JD, Willman MW, et al. (2011). Activator protein 1 (AP-1) contributes to EpCAM-dependent breast cancer invasion. Breast Cancer Res 13:R124
   Google Scholar
• Simon M, Stefan N, Plückthun A, Zangemeister-Wittke U. (2013). Epithelial cell adhesion molecule-targeted drug delivery for cancer therapy. Expert Opin Drug Deliv 10:451–68
   PubMed Web of Science ®Google Scholar
• Slanchev K, Carney TJ, Stemmler MP, et al. (2009). The epithelial cell adhesion molecule EpCAM is required for epithelial morphogenesis and integrity during zebrafish epiboly and skin development. PLoS Genet 5:e1000563
   PubMed Web of Science ®Google Scholar
• Stewart SA, Dykxhoorn DM, Palliser D, et al. (2003). Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA 9:493–501
   PubMed Web of Science ®Google Scholar
• Urban-Klein B, Werth S, Abuharbeid S, et al. (2005). RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther 12:461–6
   PubMed Web of Science ®Google Scholar
• Van Zanten J, Doornbos-Van der Meer B, Audouy S, et al. (2004). A nonviral carrier for targeted gene delivery to tumor cells. Cancer Gene Ther 11:156–64
   PubMed Web of Science ®Google Scholar
• Whitehead KA, Langer R, Anderson DG. (2009). Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 8:129–38
   PubMed Web of Science ®Google Scholar
• Xie Y, Qiao H, Su Z, et al. (2014). PEGylated carboxymethyl chitosan/calcium phosphate hybrid anionic nanoparticles mediated hTERT siRNA delivery for anticancer therapy. Biomaterials 35:7978–91
   PubMed Web of Science ®Google Scholar
• Ying B, Campbell RB. (2014). Delivery of kinesin spindle protein targeting siRNA in solid lipid nanoparticles to cellular models of tumor vasculature. Biochem Biophys Res Commun 446:441–7
   PubMed Web of Science ®Google Scholar
• Zhao Y-N, Qureshi F, Zhang S-B, et al. (2014). Novel gemini cationic lipids with carbamate groups for gene delivery. J Mater Chem 2:2920–8
   PubMed Web of Science ®Google Scholar